August 15th 2022
Before closing out their panel on HER2+ breast cancer, expert oncologists share closing thoughts and their excitement for the evolving treatment landscape.
Panelists focus on clinical trial data driving use of novel agents in the setting of HER2-low breast cancer and consider how they might select specific therapies.
August 8th 2022
Comprehensive insight on the novel treatment strategies available for patients diagnosed with HER2-low breast cancer.
Expert perspectives on the advent of HER2-low disease and how it has been historically managed since its emergence as a subset of breast cancer.
August 1st 2022
Before sharing a final review of treatment options for HER2+ metastatic breast cancer, expert oncologists highlight ongoing clinical trials in this setting.
Comprehensive discussion on how oncologists may practically select and sequence novel treatment approaches in HER2+ metastatic breast cancer.
July 25th 2022
Focusing on the management of brain metastases in HER2+ metastatic breast cancer, panelists share trial data on tucatinib and trastuzumab deruxtecan.
Homing in on trastuzumab deruxtecan, T-DXd, expert panelists review recent safety data in the setting of HER2+ metastatic breast cancer.
July 18th 2022
Shared insight on the treatment armamentarium for patients diagnosed with HER2+ metastatic breast cancer.
Before closing out their discussion on early-stage HER2+ breast cancer, expert oncologists define the value of escalating or deescalating therapy.
July 11th 2022
Subject matter experts in breast oncology discuss ongoing clinical trials in early-stage HER2+ breast cancer that focus on perioperative therapies.
Expert oncologists share their perspectives on when it would be appropriate to consider neratinib therapy in early-stage HER2+ breast cancer.
July 4th 2022
A brief discussion on the role of trastuzumab emtansine, T-DM1, in patients with early-stage HER2+ breast cancer.
Panelists review clinical data behind subcutaneous HP therapy in early stage HER2+ breast cancer and elucidate the real-world use of this approach.
June 27th 2022
Shared insight on the optimal use of HER2 dual-blockade strategies in patients with early stage HER2+ breast cancer.
Expert oncologists review adjuvant treatment strategies in early stage HER2+ breast cancer and consider when observation alone would be appropriate.
March 14th 2018
Andrew Seidman, MD, focuses on his view of the increasing role of nurse practitioners in the outpatient setting and hospitalists in the inpatient setting.
March 18th 2016
Andrew D. Seidman, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the label indication for ixabepilone (Ixempra) for the treatment of patients with aggressive breast cancer.
July 11th 2013
Andrew D. Seidman, MD, from Weill Cornell Cancer Center and Memorial Sloan-Kettering Cancer Center, discusses less surgery for patients with breast cancer.
June 28th 2013
Andrew D. Seidman, MD, from the Memorial Sloan-Kettering Cancer Center, describes his excitement over the genetic advances made in the treatment of patients with cancer.